ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Aug 15, 2017 20:00 JST
Source:
Alset International Ltd
Singapore eDevelopment's Global BioLife and Chemia Corp. to develop 3F suite of Functional Fragrances
SINGAPORE, Aug 15, 2017 - (ACN Newswire) - Singapore eDevelopment Ltd (SeD; SGX:SGE) has announced that its indirect subsidiary, Global BioLife Inc., is collaborating with U.S.-based Chemia Corporation to develop specialised fragrances which can counter mosquito-borne diseases, diminish stress and anxiety, and act in anti-viral medical applications.
3F (Functional Fragrance Formulation) is a suite of functional fragrances being developed. The first product, 3F Mosquito, is made of specialised oils sourced from botanicals which mosquitoes avoid. 3F Mosquito was designed with an objective to identify, then create a suitable formula that was pleasant, yet excels in providing layers of protection against mosquitoes.
Daryl Thompson, Global BioLife Director of Scientific Initiatives, leads the 3F research. "The specialised oils in 3F Mosquito are scientifically proven to affect a mosquito's receptors, essentially making the mosquito blind to your presence," says Thompson.
In addition to 3F Mosquito, Global BioLife and Chemia are developing fragrances as additives for use in laundry detergents, shampoos and lotions, providing additional layers of protection against mosquitoes, and developing advanced coatings for industrial and medical applications.
"Biomedical science has become increasingly vital. Global BioLife is taking steps toward providing solutions to issues that have plagued the biomedical field for decades. This working collaboration marks a first steps in actively changing the game of healthcare," said Chan Heng Fai, SeD Executive Chairman and Chief Executive Officer, and a Global BioLife Director.
Global BioLife is an 80%-held subsidiary of SeD wholly-owned Global BioMedical Inc. The remaining shareholding in Global BioLife is held by Thompson's GRDG Sciences LLC and Australia Securities Exchange-listed Holista CollTech Limited, in equal proportions of 10% each.
About Chemia Corporation
Chemia Corporation provides high quality, cost effective fragrances to the manufacturers of personal care, household and industrial & institutional products. Thomas A. Meyer is the Vice-President of Innovation and Sustainability. For further information, please visit www.chemiacorp.com.
About GRDG Sciences LLC
GRDG Sciences LLC is a natural products discovery drug research company incorporated in Florida, USA. The Company was set up by natural products scientist Daryl Thompson. Thompson is a biochemist, nominated for the Nobel Prize in 2015 and 2016 for his research in pandemic technology.
About Holista CollTech Ltd
Holista CollTech is incorporated in Australia and listed on the Australian Securities Exchange. A research-driven biotechnology company, Holista focuses on research and development of product in the natural products space. Founder and Chief Executive Officer Dr Rajen Manicka holds a PhD in Holistic Medicine and a Masters of Business Administration. For further information, please visit www.holistaco.com.
About Singapore eDevelopment Ltd
Singapore eDevelopment Ltd (SeD) was incorporated on 9 Sept 2009, and listed by SGX Catalist (SGX:SGE) in July 2010. SeD is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg.
Issued for the Company:
WeR1 Consultants Pte Ltd
Ian Lau
Tel : +65 6737 4844
Email:
ianlau@wer1.net
Source: Alset International Ltd
Sectors: Healthcare & Pharm, Funds & Equities, Cosmetics, Spec.Chem
Copyright ©2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
Toyota Motor Corporation aims to join Daimler Truck and Volvo Group as equal shareholder in the fuel cell joint venture cellcentric
Mar 31, 2026 23:39 JST
Honda Announces the Establishment of PathAhead Co., Ltd., a Startup Originated from IGNITION, a Honda New Business Creation Program
Mar 31, 2026 21:58 JST
Hitachi Digital Services Strengthens OT-IT Integration with Manufacturing Operations Management Platform
Mar 31, 2026 19:14 JST
Fujitsu and Osaka University of Health and Sport Sciences partner to innovate sports performance with skeleton recognition AI
Mar 31, 2026 17:42 JST
DOCOMO and SK Telecom Publish White Paper on Requirements for Advancing vRAN and AI-RAN in Mobile Networks
Mar 31, 2026 11:00 JST
NEC Supports Ooredoo Algeria in Modernizing Enterprise Network Security with high-performance next-generation firewalls (NGFW)
Mar 31, 2026 10:50 JST
MOL and Hitachi Launch Initiative to Convert Used Ships into Floating Data Centers
Mar 30, 2026 19:21 JST
Resona Holdings, BrainPad, and Fujitsu sign basic agreement for collaboration to transform financial operations with data and AI and advance next-generation data utilization
Mar 30, 2026 15:55 JST
MHI Innovative Combustion Dynamics Laboratory is Established at Kyoto University with the Aim of Developing and Socially Implementing World-Leading Technology
Mar 30, 2026 12:53 JST
Fujitsu launches generative AI service that analyzes source code and automatically generates design documents
Mar 30, 2026 10:41 JST
Application Submitted for LENVIMA(R) (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG(R) (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy
Mar 27, 2026 20:14 JST
Hitachi and MUFG Bank expand NextGen model to finance vehicles and charging infrastructure for decarbonized mobility
Mar 27, 2026 19:44 JST
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
Mar 27, 2026 18:19 JST
New "L00 Series" Train for the Seibu Railway's Yamaguchi Line Begins Commercial Operation
Mar 27, 2026 16:51 JST
Fujitsu develops high-sensitivity, high-resolution infrared sensor to expand monitoring capabilities in defense and disaster prevention
Mar 27, 2026 14:07 JST
Sharp Develops Long-Range Video Monitoring Technology
Mar 26, 2026 22:39 JST
OKI and Hitachi Agree to Integrate Businesses Related to Automated Teller Machines (ATMs) and Other Automated Equipment
Mar 26, 2026 22:10 JST
Hitachi Rail to manufacture rolling stock for Seibu Railway"s new Fine Dining Train
Mar 26, 2026 15:13 JST
Royal Healthcare in Singapore provides NEC's "FonesVisuas Test" for Disease Risk Prediction
Mar 26, 2026 11:21 JST
MHI-AP Awarded Boiler Retrofit Contract for Waste-to-Energy Facility in Singapore
Mar 26, 2026 11:07 JST
More Latest Release >>
Related Release
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities
March 23 2022 09:00 JST
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option
February 21 2022 12:00 JST
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc.
October 05 2020 15:25 JST
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance
September 18 2020 17:00 JST
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development
July 31 2020 15:00 JST
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance
June 24 2020 14:00 JST
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal
June 17 2020 18:00 JST
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts
June 01 2020 13:00 JST
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
April 24 2020 10:00 JST
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak
March 18 2020 11:00 JST
More Press release >>